Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941

Journal of Urology

Volumn 178, Issue 5, 2007, Pages 1901-1905

  Escudier, Bernard ^a   Choueiri, Toni K ^f   Oudard, Stéphane ^b   Szczylik, Cezary ^g   Négrier, Sylvie ^c   Ravaud, Alain ^d   Chevreau, Christine ^e   Venner, Peter ^h   Champagne, Pierre ⁱ   Croteau, Daniel ⁱ   Dupont, Eric ⁱ   Hariton, Claude ⁱ   Bukowski, Ronald M ^f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c CENTRE LÉON BÉRARD   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g MILITARY INSTITUTE OF MEDICINE   (Poland)

^h CROSS CANCER INSTITUTE   (Canada)

ⁱ Les Laboratoires Æterna Inc 1405   (Canada)

Author keywords

carcinoma; kidney; neoplasm metastasis; prognosis; renal cell; shark cartilage extract AE 941

Indexed keywords

AE 941; ALKALINE PHOSPHATASE; ALPHA INTERFERON; BEVACIZUMAB; CALCIUM; INTERLEUKIN 2; LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; FEMALE; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ALBERTA; BIOPSY; CARCINOMA, RENAL CELL; CARTILAGE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OHIO; POLAND; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUEBEC; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TISSUE EXTRACTS; TREATMENT FAILURE;

EID: 35148862970     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.07.035     Document Type: Article

References (20)

1. Pyrhonen S., Salminen E., Ruutu M., Lehtonen T., Nurmi M., Tammela T., et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 (1999) 2859
2. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688
3. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427
4. Escudier B., Szczylik C., Eisen T., Szczylik C., Oudard S., Siebels M., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). N Engl J Med 356 (2007) 125
5. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516
6. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). N Engl J Med 356 (2007) 115
7. Elson P.J., Witte R.S., and Trump D.L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48 (1988) 7310
8. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530
9. Negrier S., Escudier B., Gomez F., Douillard J.Y., Ravaud A., Chevreau C., et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 13 (2002) 1460
10. Atzpodien J., Royston P., Wandert T., and Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88 (2003) 348
11. Mekhail T.M., Abou-Jawde R.M., Boumerhi G., Malhi S., Wood L., Elson P., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832
12. Choueiri T.K., Rini B.I., Garcia J.A., Baz R., Abou-Jawde R., Thakkar S.G., et al. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol 18 (2007) 249
13. Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454
14. Escudier B., Venner P., Bukowski R., Szczylik C., Oudard S., Champagne P., et al. Phase III trial of Neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. J Clin Oncol 22 suppl. (2003) 844 abstract
15. Kaplan E.P., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457
16. Cox D., and Oakes D. Analysis of Survival Data (1990), Chapman and Hall, New York
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163
18. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., et al., Groupe Francais d'Immunotherapie. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338 (1998) 1272
19. Boumerhi G., Mekhail T.M., Abou-Jawde R.M., Malhi S., Olencki T., Leschinsky A., et al. Prognostic factors for survival in previously treated patients (pts) with metastatic renal cell cancer (RCC). J Clin Oncol 22 suppl (2003) 16s abstract 1647
20. Donskov F., and von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 1997